Choose Your Country or Region

Nivolumab (anti-PD-1)

Synonyms: BMS-936558, ONO-4538, MDX-1106

Catalog No.A2002 Purity: 99.87%

Nivolumab (anti-PD-1) is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. MW : 143.597 KD.

Nivolumab (anti-PD-1) Chemical Structure

Selleck's Nivolumab (anti-PD-1) has been cited by 61 publications

Purity & Quality Control

Batch: Purity: 99.87% Protein concentration: 8.8 mg/ml Endotoxin Level: <1 EU/mg

99.87

Choose Selective PD-1/PD-L1 Inhibitors

Biological Activity

Description

Features

Human IgG4

Targets

PD-1/PD-L1 interaction ^[2] (Cell-free assay)	PD-1/PD-L2 interaction ^[2] (Cell-free assay)
2.52 nM	2.59 nM

In Vitro
In vitro	The cell binding ratio of ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.^[1]
Cell Research:	Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. ¹²⁵I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×10⁶ cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. ¹²⁵I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.

In Vitro

In vitro

The cell binding ratio of ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA to PD-1 is 13.78 ± 2.90% and 10.22 ± 2.62%, respectively. Conjugating of DTPA does not affect targeting of Nivolumab to PD-1 in vitro.^[1]

Cell Research:

Splenocytes were isolated from the spleens obtained from humanized PD-1 over-expressing mice following standard protocol. ¹²⁵I labeled Nivolumab and Nivolumab-DTPA, respectively. To perform co-culture, ¹²⁵I-Nivolumab and ¹²⁵I-Nivolumab-DTPA (0.37 MBq/µg) were added to the freshly isolated splenocytes (1×10⁶ cells) grown in 6-well plates, respectively. After incubation for 12 h at 4°C, cells were collected after rinsing three times with PBS. ¹²⁵I radioactivity was determined in a gamma counter to evaluate their binding efficiency to PD-1.

In Vivo
In vivo	In SPECT images, lesions with high ^99mTc-DTPA-nivolumab uptake and relatively clear background are shown at 6 h. Thereafter, the suspected intestinal thickening in Gd-free T1WI is observed at 2 h after the addition of Gd-DTPA-nivolumab.^[1]
Animal Research	Animal Models: CRC mouse models (highly expressed human PD-1 antigen) Dosages: 11.1 MBq/10 μg Administration: i.v. Reference: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883027/

References
[1] Li D, et al. Front Bioeng Biotechnol. 2022 Feb 14;10:839756.

References

[1] Li D, et al. Front Bioeng Biotechnol. 2022 Feb 14;10:839756.

Product Details

CAS No.	946414-94-4
Isotype	Human IgG4
Source	CHO cells
Formulation	PBS buffer, pH 7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Frequently Asked Questions

Question 1:
How to store the antibody?

Answer:
Store the undiluted solution at 4 °C in the dark. Freezing antibodies can result in a loss of activity caused by the freezing/thawing process. Diluting antibodies to working concentrations and storing at 4°C for more than a day should be avoided. Additionally, make sure to keep the antibody sterile. Under these storage conditions, your antibodies should remain active for up to one year and oftentimes longer.